ORIGINAL ARTICLE

Korean J Intern Med 2021;36:659-667 https://doi.org/10.3904/kjim.2020.077



Effect of urinary angiotensinogen and high-salt diet on blood pressure in patients with chronic kidney disease: results from the Korean Cohort Study for Outcome in Patients with Chronic Kidney Disease (KNOW-CKD)

Ha Yeon Kim¹, Hong Sang Choi¹, Chang Seong Kim¹, Eun Hui Bae¹, Seong Kwon Ma¹, Su-Ah Sung², Seung Hyeok Han³, Kook-Hwan Oh⁴, Curie Ahn⁴, and Soo Wan Kim¹

¹Department of Internal Medicine, Chonnam National University Medical School, Gwangju; ²Department of Internal Medicine, Nowon Eulji Medical Center, Eulji University, Seoul; ³Department of Internal Medicine and Institute of Kidney Disease Research, Yonsei University College of Medicine, Seoul; ⁴Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea

Received: February 27, 2020 Revised : April 10, 2020 Accepted: April 23, 2020

Correspondence to Soo Wan Kim, M.D.

Department of Internal Medicine, Chonnam National University Medical School, 42 Jebong-ro, Dong-gu, Gwangju 61469, Korea Tel: +82-62-220-6271, Fax: +82-62-225-8578 E-mail: skimw@chonnam.ac.kr https://orcid.org/0000-0002-3540-9004 **Background/Aims:** This study aimed to investigate whether urinary angiotensinogen (UAGT) excretion was associated with elevated blood pressure in patients with chronic kidney disease (CKD) and to evaluate the relationship among blood pressure, intra-renal renin-angiotensin system (RAS) activity, and dietary sodium in patients with CKD.

Methods: Participants from the Korean Cohort Study for Outcome in Patients with Chronic Kidney Disease (KNOW-CKD) were included. Of the total cohort of 2,238 individuals with CKD, we included 1,955 participants who underwent complete 24-hour urinary sodium (24-hour UNa) analysis. They were categorized into three groups according to three tertiles of their 24-hour UNa, reflecting daily salt intake. To measure intra-renal RAS activity, the UAGT excretion was assayed with an enzyme-linked immunosorbent assay.

Results: Elevated 24-hour UNa levels, logarithm of UAGT-to-creatinine ratio (UAGT/Cr), increased waist-to-hip ratio, and decreased estimated glomerular filtration rate were the risk factors for increased systolic blood pressure. Systolic blood pressure showed a positive correlation with 24-hour UNa levels and logarithm of UAGT/Cr.

Conclusions: UAGT and urinary sodium excretion are independent determinants of systolic blood pressure in patients with CKD. These findings suggest that increased systolic blood pressure in CKD patients is associated with both increased dietary sodium levels and intra-renal RAS activity. The risk of elevated systolic blood pressure in the 3rd tertile of both the UAGT/Cr and 24-hour UNa groups was about 2.3 times higher than that in the reference group.

Keywords: Urine angiotensinogen; 24-Hour urine-sodium excretion; Hypertension; Chronic kidney disease



INTRODUCTION

Increased renin-angiotensin system (RAS) activity is an independent risk factor for hypertension and when it is accompanied by sodium retention following volume expansion, the risk intensifies. In general, as a consequence of enhanced sodium retention, the activity of the systemic RAS is suppressed [1,2]. The question of whether salt intake leads to hypertension directly has been controversial for decades. Extensive studies have been conducted to identify the pathophysiological mechanisms responsible for the heterogeneity of responses due to increased salt intake [3-5]. Inappropriate or paradoxical activation of the intra-renal RAS, oxidative stress, and inflammatory cytokines in the kidney are key factors that lead to the development of salt - sensitive hypertension [6,7]. The intra-renal RAS, independent of the systemic RAS, plays an important role in the pathophysiology of hypertension and renal injury [6,8]. Moreover, high sodium diet modulates renal hemodynamics and tubular resorptive function to enhance sodium retention, volume expansion, and the development of hypertension [9]. Hypertension is associated with both increased intra-renal RAS activity and volume expansion [10], and it gets worse when these exist concomitantly.

Angiotensinogen (AGT) is the only known substrate for renin, the rate-limiting enzyme of the RAS, and changes in AGT levels as well as renin levels can control the activity of the RAS [11]. Angiotensin II in renal tissues is locally generated from AGT produced by the proximal tubule cells and delivered in the kidney. Urinary angiotensinogen (UAGT) may serve as a new biomarker to reflect the activity of intra-renal RAS activity, because it is derived largely from proximal tubular AGT. In addition, urinary excretion of AGT highly correlated with intra-renal AGT and angiotensin II levels [12-19].

The objective of the present study was to investigate whether UAGT excretion was associated with elevated blood pressure in chronic kidney disease (CKD) patients, and to evaluate the relationship between blood pressure, intra-renal RAS activity, and dietary sodium in patients with CKD.

METHODS

Study subjects

The design of the Korean Cohort Study for Outcome in Patients with Chronic Kidney Disease (KNOW-CKD) study has been described in detail in a previous study [20]. KNOW-CKD is a patient-based multicenter cohort study involving nine tertiary-care general hospitals in Korea. The KNOW-CKD enrolled ethnic Korean patients with CKD of stages 1 to 5 aged between 20 and 75 years. A total of 2,238 adults with CKD were enrolled from all participating centers between 2011 and 2015 in an ongoing prospective cohort study in collaboration with a multicenter cohort study. Of the total 2,238 patients, 1,955 patients who completed the measurements of 24-hour urinary sodium (24-hour UNa) excretion were included our analysis. The estimated glomerular filtration rate (eGFR) was calculated using the CKD Epidemiology Collaboration (CKD-EPI) creatinine (Cr) equation [21]. The serum and urine samples were subsequently collected on a regular basis according to the standardized protocol. All data, including clinical information, laboratory results, and outcomes were entered into a web-based, electronic, case-reporting form. The patients were divided into three groups according to their 24-hour UNa and UAGT to Cr (UAGT/Cr) ratio values.

Clinical data and laboratory analyses

The clinical data, including detailed demographic information and baseline laboratory results, were extracted from the electronic data management system (PhactaX, Seoul, Korea). The morning spot urine samples were collected from all patients to measure the UAGT, urinary Cr, albumin, and protein levels. The urine samples were centrifuged at 1,500 rpm for 10 minutes at 4°C. The urinary supernatants were pooled, and the UAGT concentrations were measured using human AGT ELISA kits (IBL, Takasaki, Japan). Intra-assay and inter-assay coefficients of variation for the human AGT ELISA kits were 4.4% and 4.3%, respectively [22]. The urinary concentrations of AGT and albumin were normalized to the urinary Cr level. The resting blood pressure was measured at each clinic using an electronic sphygmomanometer. Based on the etiology of CKD, the patients were categorized as having glomerulonephritis, diabetic nephropathy, hypertensive nephropathy, and polycystic kidney disease.



Statistical analysis

R language version 3.3.3 (R Foundation for Statistical Computing, Vienna, Austria) and T&F program ver. 2.0 (YooJin BioSoft, Goyang, Korea) were used for all statistical analyses. The data were expressed as mean ± SD for continuous variables. The continuous variables, including systolic blood pressure (SBP), diastolic blood pressure (DBP), 24-hour UNa, and UAGT/Cr were transformed to categorical variables having three subgroups corresponding to the three respective tertile ranges. For the continuous variables, Pearson correlation and Spearman correlation coefficient were computed. Linear regression analysis was performed to analyze the effect of each clinical measurement on the continuous response of SBP. Multivariable linear regression analysis was performed using backward stepwise procedure as a variable selection method to minimize Akaike information criterion (AIC). Significance level of 0.1 was set for the univariable analysis to select initial input variables for the multivariable analysis (Supplementary Table 1).

Binary logistic regression analysis was performed to analyze the effect of each clinical measurement on the binary response of SBP (1st and 2nd group vs. 3rd group). For analyzing the combined effect of more than two variables on the SBP (1st and 2nd group vs. 3rd group), multivariable logistic regression analysis was performed using backward stepwise procedure as a variable selection method to minimize AIC. Significance level of 0.1 was set for the univariable analysis to select the initial input variables for the multivariable analysis.

Ethical approval and informed consent

The study protocol was approved by the Institutional Review Board at each participating clinical center—i.e., Seoul National University Hospital (1104-089-359), Seoul National University Bundang Hospital (B-1106/129-008), Yonsei University Severance Hospital (4-2011-0163), Kangbuk Samsung Medical Center (2011-01-076), Seoul St. Mary's Hospital (KC11OIMI0441), Gil Hospital (GIRBA2553), Eulji General Hospital (201105-01), Chonnam National University Hospital (CNUH-2011-092), and Inje University Pusan Paik Hospital (11-091) in 2011. Written informed consent was obtained from all study participants. This study was conducted in accordance with the principles of the Declaration of Helsinki.

RESULTS

Baseline characteristics and comparison of study participants according to 24-hour UNa excretion

A total of 1,955 patients (mean age, 48.7 ± 12.4 years; 60.7% male population) were included in this study. The etiology of primary renal disease in the subjects was hypertension in 18.4%, autosomal dominant polycystic kidney disease in 17.3%, diabetes in 23.6%, and glomerulonephritis in 34.4% of the subjects. The mean 24-hour UNa level was 158.33 ± 70.10 mEq/day. Table 1 represents the demographics and clinical features in the three 24-hour UNa categories. In the group with high 24-hour UNa excretion, the proportion of males, body mass index, waist-to-hip ratio, SBP, and DBP was higher. In addition, in the group with high 24-hour UNa, RAS blockers (angiotensin-converting enzyme inhibitors and angiotensin II receptor blocker) were more used, and serum hemoglobin and fasting blood glucose were also higher. On the other hand, mean UAGT/Cr was 20.03, 18.52, and 20.39 μ g/g respectively, in the three groups and there were no significant differences among them. There were no pertinent differences in values of serum albumin, sodium, potassium concentration and urinary albumin Cr ratio. The 24-hour UNa had no correlation with logarithm (Log) of UAGT/Cr (coefficient R, 0.005; p = 0.831; not shown).

Factors affecting SBP

We evaluated factors affecting SBP in CKD patients. SBP was related to waist-to-hip ratio, 24-hour UNa, Log UAGT/Cr, eGFR < 15 mL/min/1.73 m² (Table 2). SBP had a positive correlation with DBP, 24-hour UNa, and Log UAGT/Cr (Fig. 1).

Effect of 24-hour UNa excretion and UAGT/Cr on SBP

Fig. 1 represents the single regression analysis for SBP. SBP revealed a positive association with DBP (coefficient *R*, 0.633; *p* < 0.001), Log UAGT/Cr (coefficient *R*, 0.1; *p* < 0.001), and 24-hour UNa levels (coefficient *R*, 0.088; *p* < 0.001). Patients were divided into nine groups based on the third tertile of 24-hour UNa and UAGT/Cr. Table 3 showed that in the three groups with the lowest 24-hour UNa (1st tertile), SBP increased as the UAGT/Cr increased. Similarly, in the three groups with the lowest



Table 1. Baseline characteristics and clinical features of the patients in the different tertile groups based on the 24-hour UNa excretion level

¥7	77-1-1	2	6 1		
variable	Total	1st tertile	2nd tertile	nd tertile 3rd tertile	
Patient	1,955 (100)	650 (33.3)	653 (33.4)	652 (33.4)	
24-hour UNa, mEq/day	158.33 ± 70.10	87.55 ± 26.44	150.35 ± 15.75	236.91 ± 50.52	< 0.001
Male sex	1,186 (60.7)	340 (52.3)	361 (55.3)	485 (74.4)	< 0.001
Age, yr	48.7 ± 12.4	49.3 ± 12.7	48.9 ± 12.0	48.0 ± 12.2	0.076
Etiology of CKD					0.0015
Diabetic nephropathy	462 (23.6)	157 (24.2)	152 (23.3)	153 (23.5)	0.926
Hypertensive nephropathy	360 (18.4)	127 (19.5)	107 (16.4)	126 (19.3)	0.260
Glomerulonephritis	673 (34.4)	208 (32.0)	226 (34.6)	239 (36.7)	0.208
Polycystic kidney disease	338 (17.3)	122 (18.8)	132 (20.2)	84 (12.9)	0.001
eGFR category, mL/min/1.73 m ²					< 0.001
>90	237 (12.1)	53 (8.2)	89 (13.6)	95 (14.6)	
60–90	364 (18.6)	102 (15.7)	130 (19.9)	132 (20.2)	
45-59	353 (18.1)	123 (18.9)	102 (15.6)	128 (19.6)	
30-44	431 (22.0)	133 (20.5)	150 (23.0)	148 (22.7)	
15–29	449 (23.0)	182 (28.0)	149 (22.8)	118 (18.1)	
< 15	121 (6.2)	57 (8.8)	33 (5.1)	31 (4.8)	
Body mass index, kg/m ²	24.57 ± 3.40	23.69 ± 3.35	24.56 ± 3.28	25.54 ± 3.34	< 0.001
Waist-to-hip ratio, m/m	0.9 ± 0.07	0.89 ± 0.07	0.90±0.06	0.91 ± 0.06	< 0.001
Systolic blood pressure, mmHg	128.50 ± 16.51	127.22 ± 16.98	127.74 ± 15.83	130.99 ± 16.53	< 0.001
Diastolic blood pressure, mmHg	76.85 ± 11.17	75.73 ± 11.26	76.42 ± 11.01	78.20 ± 11.42	0.002
eGFR, mL/min/1.73 m ²	50.41 ± 30.17	44.91 ± 27.37	51.98 ± 30.70	54.93 ± 30.69	< 0.001
ACEIs or ARBs	1,675 (85.7)	544 (83.7)	549 (84.2)	582 (89.3)	0.006
UACR, g/g	0.71 ± 1.27	0.55 ± 0.98	0.67 ± 1.17	0.80 ± 1.51	0.290
Hemoglobin, g/dL	12.83 ± 2.02	12.49 ± 1.92	12.74 ± 1.92	13.35 ± 2.08	< 0.001
Fast blood glucose, mg/dL	111.00 ± 39.65	108.32 ± 36.89	109.88 ± 38.83	114.70 ± 42.00	< 0.001
Albumin, mg/dL	4.17 ± 0.43	4.19 ± 0.39	4.17 ± 0.44	4.21 ± 0.43	0.125
Sodium, mEq/L	140.82 ± 2.46	140.82 ± 2.41	140.83 ± 2.54	140.84 ± 2.44	0.796
Potassium, mEq/L	4.63 ± 0.57	4.64 ± 0.58	4.62 ± 0.57	4.64 ± 0.56	0.700
Uric acid, mg/dL	7.02 ± 1.92	7.18 ± 2.00	6.85 ± 1.87	6.98 ± 1.86	0.008
UAGT/Cr, µg/g	19.40 ± 42.28	20.03 ± 49.39	18.52 ± 35.34	20.39 ± 43.52	0.835
Log UAGT/Cr, µg/g	0.75 ± 0.68	0.74 ± 0.69	0.76 ± 0.66	0.75 ± 0.69	0.871

Values are presented as number (%) or mean ± SD,

24-hour UNa, 24-hour urinary sodium; CKD, chronic kidney disease; eGFR estimated glomerular filtration rate; ACEI, angiotensin-converting-enzyme inhibitors; ARB, angiotensin receptor blocker; UACR, urine albumin-to-creatinine ratio; UAGT, urine angiotensinogen; Log, logarithm; Cr, creatinine.

UAGT/Cr values (1st tertile), SBP increased significantly as the 24-hour UNa increased. SBP was the highest (with a mean blood pressure of 131.873 \pm 1.384 mmHg) in the cluster with the highest tertiles (third groups) of both 24-hour UNa and UAGT/Cr compared to that of the other groups (Table 3).

After adjusting for clinical and basic demographic factors including age, sex, five stages according to the eGFR

кјім≁

m 11 m 1. C.1 1.•1 1	1	1 1 1	11.10	. 1. 11 1
Table 2. Results of the multiple l	linear regression analy	vsis using the backwar	d stepwise method for s	vstolic blood pressure

Predictor	Regression coefficient (95% CI)	p value
Age	-0.004 (-0.116 to 0.108)	0.949
Female	0.168 (–2.694 to 3.030)	0.908
Waist-to-hip ratio	38.805 (18.035 to 59.575)	< 0.001
24-hour UNa	0.020 (0.002 to 0.038)	0.027
Log UAGT/Cr	1.950 (0.103 to 3.798)	0.039
Log UACR	1.577 (–0.448 to 3.602)	0.127
eGFR category ^a , mL/min/1.73 m ²		
60–90	2.421 (–2.013 to 6.855)	0.285
30-59	-0.237 (-4.644 to 4.170)	0.916
15–29	3.599 (–1.605 to 8.803)	0.176
< 15	8.015 (1.664 to 14.367)	0.045

CI, confidence interval; 24-hour UNa, 24-hour urinary sodium; Log, logarithm; UAGT/Cr, urinary angiotensinogen-to-creatinine ratio; UACR, urinary albumin-to-creatinine ration; eGFR, estimated glomerular filtration rate. ^aReference, > 90 mL/min/1.73 m².



Figure 1. Results of the single regression analysis for systolic blood pressure. Relationship between systolic blood pressure and (A) diastolic blood pressure, (B) 24-hour urinary sodium (24-hour UNa) excretion, and (C) logarithm of urine angiotensino-gen-to-creatinine ratio (Log UAGT/Cr).

category, waist-to-hip ratio, body mass index, and hemoglobin level, the odds of having the 3rd tertile (highest) of SBP in each patient group was analyzed by multivariable binary logistic regression (Table 4). The odds ratio of the group with the lowest 24-hour UNa and UAGT/Cr was used as a reference. In this study, the risk of elevated SBP in the 3rd tertile of both the UAGT/Cr and 24-hour UNa groups was about 2.3 times higher than that in the reference group. High SBP was associated with elevated levels of both UAGT/Cr and 24-hour UNa.

In the three groups with the lowest 24-hour UNa (1st tertile), odds of an elevated SBP increased with a large difference as the UAGT/Cr increased. Similarly, in the three groups with the lowest UAGT/Cr values (1st tertile), odds of SBP increased considerably as the 24-hour UNa increased. Therefore, when the value of either 24-



a hour UNe ²	UAGT/Cr					
24-11001 O'Na	1st tertile	2nd tertile	3rd tertile	pvalue		
1st tertile	125.269 ± 1.384 (n = 169)	129.885 ± 1.388 (n = 170)	129.077 ± 1.392 (n = 168)	0.049		
2nd tertile	126.394 ± 1.433 (n =164)	130.09 ± 1.347 (n = 181)	129.293 ± 1.378 (n = 169)	0.110		
3rd tertile	130.454 ± 1.445 (n = 168)	128.902 ± 1.433 (n = 163)	131.873 ± 1.384 (n = 168)	0.212		
p value	0.041	0.882	0.204			

Table 3. Systolic blood pre	ssure (mmHg) according t	o the 24-hour UNa levels	(mEq/day) and	UAGT/Cr (µg/g)
-----------------------------	--------------------------	--------------------------	---------------	----------------

Values are presented as mean \pm SD (n, sample number in each subgroup).

24-hour UNa, 24-hour urinary sodium; UAGT/Cr, urinary angiotensinogen-to-creatinine ratio.

 $a^{a}p = 0.009$; *p* value is computed using a *post hoc* algorithm of Tukey after performing one-way ANCOVA.

Table 4.	OR (05% C	I) for the	ard tertile	(highest) of s	vstolic blood	pressure accordin	g to the 2	-hour UN:	a and UAGT/	Cr
1 4010 41	01(9)/00	I IOI the	Ju terthe	mgnese	JOID	ystone blood	pressure accordin	g to the 2			

a , hour UNa	UAGT/Cr					
24-nour ONa	1st tertile	2nd tertile	3rd tertile			
1st tertile	1 (reference)	1.782 (1.095–2.899) p = 0.02	2.289 (1.404–3.729) ⊉ ≤ 0.001			
2nd tertile	1.313 (0.798–2.158) p = 0.283	1.715 (1.060–2.777) p = 0.028	1.667 (1.021–2.724) p = 0.041			
3rd tertile	2.121 (1.298–3.466) p = 0.003	1.564 (0.953 – 2.567) p = 0.077	2.395 (1.478 – 3.879) ⊉ ≤ 0.001			

From multivariable binary logistic regression models stratified by 3 × 3 groups and adjusted for age, sex, 5 stages according to the estimated glomerular filtration rate category, waist-to-hip ratio, body mass index, and hemoglobin level (g/dL). OR, odds ratio; CI, confidence interval; 24-hour UNa, 24-hour urinary sodium; UAGT/Cr, urinary angiotensinogen-to-creatinine ratio.

hour UNa or UAGT/Cr was low, SBP was more strongly affected by the other corresponding variable.

DISCUSSION

The present study demonstrated that enhanced intra-renal RAS activity and high urinary sodium excretion were associated with high SBP in CKD patients. It was conducted by using data from the KNOW-CKD study, which was a well-designed, cross-sectional study of 2,238 patients with CKD. The group with the highest tertile of UAGT/Cr and 24-hour UNa had the highest tertile SBP with an odds ratio of 2.395 compared to the rest of the group. The high salt intake and intra-renal RAS activity may be related to the group with the increased SBP.

Many observational studies have evaluated the relationship between high salt intake and blood pressure, and obtained conflicting results. Recently, however, numerous observational studies, Cochrane meta-analyses, and randomized trials have revealed that there is a close association between salt intake and elevated blood pressure [23-25]. Our study showed that for every 100 mEq/day increase of 24-hour UNa, SBP increased by 2.0 mmHg (p = 0.027) (Table 2). This is a small change compared to the results of the Korean National Health and Nutritional Examination Survey, which revealed that as 24-hour UNa increased by 100 mEq/day, SBP increased by 6.1 mmHg [26]. This may be explained by the fact that sensitivity to changes in blood pressure due to sodium intake is very distinctive for an individual and is known to be associated with genetic susceptibility [27]. In salt-sensitive hypertensive patients, a long-term high-salt diet can cause hypertension and renal injury, more prominently than in the general population [28-31]. When sodium retention occurs, the intra-renal RAS activity may be elevated, which may be the mechanism underlying salt-induced hypertension, which causes

кјім≁

hypertensive renal injury [7]. Additionally, salt-sensitive patients exhibited higher blood pressure and less plasma renin activity suppression in response to elevated sodium intake [32-34]. In our present study, higher the salt intake, higher the SBP and DBP. This may affect CKD progression, even among those with better renal function and high eGFR. This is because high-salt diet is associated with increased renal injury and significant changes in the gene expression of renal cytokines that are related to the pro-inflammatory response and endothelial dysfunction, and attenuated cell differentiation and survival [35].

While previous studies conducted in patients classified as salt-sensitive groups have shown that high salt intake leads to an increase in intra-renal RAS activity, our study did not show a correlation between UAGT excretion and urinary sodium excretion. Understandably, as in our study we had not distinguished between salt-sensitive and salt-resistant groups. However, it showed that UAGT excretion was independently associated with SBP. It was also demonstrated that the group with the highest urinary sodium excretion and UAGT excretion showed the greatest odds of presenting with high SBP.

The strength of the present study is that it provides evidence in a relatively large, well-designed CKD patient cohort. To our knowledge, this was the first Asian study to show an effect of both UAGT and high-salt diet on SBP in CKD patients. Regardless, this study had several limitations. First, owing to the cross-sectional nature of the study, it was difficult to demonstrate the cause-effect relationship between SBP and 24-hour UNa and UAGT/Cr. Second, more than 85% of the patients with CKD were on RAS blocker; these patients could not be excluded or analyzed as a different group. Third, it does not provide insights on 24-hour UNa and daily sodium intake in CKD patients with impaired tubular function and sodium reabsorption.

In conclusion, both the intra-renal RAS and high-salt diet could be related to the elevation of SBP in CKD patients. Modulating and monitoring each of these in hypertensive CKD patients may help alleviate renal injury. While treating patients with hypertension, both the amount of sodium in the diet and the intra-renal RAS need to be considered. More research in the future will be needed to determine if dietary sodium restriction could be a more effective treatment for patients with increased intra-renal RAS activity.

KEY MESSAGE

- Systolic blood pressure (SBP) showed a positive correlation with 24-hour urinary sodium (24hour UNa) and urine angiotensinogen-to-creatinine ratio (UAGT/Cr), in patients with chronic kidney disease (CKD).
- 2. SBP was the highest in the group with the highest 24-hour UNa (third tertile) and the group with the highest UAGT/Cr (third tertile).
- 3. These findings suggest that increased SBP in CKD patients is associated with both increased dietary sodium and intra-renal renin-angiotensin system activity.

Conflict of interest

No potential conflict of interest relevant to this article was reported.

Acknowledgments

This research was assisted by the Research Program funded by the Korea Centers for Disease Control and Prevention (2011E3300300, 2012E3301100, 2013E3301600, 2013E3301601, 2013E3301602, 2016E3300200), the Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Science, ICT & Future Planning (2015R1D1A1A01061037), by the Bio & Medical Technology Development Program of the NRF funded by the Korean government, MSIT (2017M3A9E8023001), and by a grant (BCR18015-1) of Chonnam National University Hospital Biomedical Research Institute.

REFERENCES

- 1. Griffing GT, Wilson TE, Melby JC. Alterations in aldosterone secretion and metabolism in low renin hypertension. J Clin Endocrinol Metab 1990;71:1454-1460.
- 2. Fisher ND, Hurwitz S, Ferri C, Jeunemaitre X, Hollenberg NK, Williams GH. Altered adrenal sensitivity to angiotensin II in low-renin essential hypertension. Hypertension

кјім≁

1999;34:388-394.

- Kopkan L, Hess A, Huskova Z, Cervenka L, Navar LG, Majid DS. High-salt intake enhances superoxide activity in eNOS knockout mice leading to the development of salt sensitivity. Am J Physiol Renal Physiol 2010;299:F656-F663.
- Blaustein MP, Leenen FH, Chen L, et al. How NaCl raises blood pressure: a new paradigm for the pathogenesis of salt-dependent hypertension. Am J Physiol Heart Circ Physiol 2012;302:H1031-H1049.
- Hauck C, Frishman WH. Systemic hypertension: the roles of salt, vascular Na+/K+ ATPase and the endogenous glycosides, ouabain and marinobufagenin. Cardiol Rev 2012;20:130-138.
- Kobori H, Nangaku M, Navar LG, Nishiyama A. The intrarenal renin-angiotensin system: from physiology to the pathobiology of hypertension and kidney disease. Pharmacol Rev 2007;59:251-287.
- Majid DS, Prieto MC, Navar LG. Salt-sensitive hypertension: perspectives on intrarenal mechanisms. Curr Hypertens Rev 2015;11:38-48.
- Navar LG, Kobori H, Prieto MC, Gonzalez-Villalobos RA. Intratubular renin-angiotensin system in hypertension. Hypertension 2011;57:355-362.
- 9. Weinberger MH. Sodium, potassium, and blood pressure. Am J Hypertens 1997;10(5 Pt 2):46S-48S.
- Rodriguez-Iturbe B, Romero F, Johnson RJ. Pathophysiological mechanisms of salt-dependent hypertension. Am J Kidney Dis 2007;50:655-672.
- Brasier AR, Li J. Mechanisms for inducible control of angiotensinogen gene transcription. Hypertension 1996;27(3 Pt 2):465-475.
- 12. Kobori H, Harrison-Bernard LM, Navar LG. Urinary excretion of angiotensinogen reflects intrarenal angiotensinogen production. Kidney Int 2002;61:579-585.
- 13. Kobori H, Nishiyama A, Abe Y, Navar LG. Enhancement of intrarenal angiotensinogen in Dahl salt-sensitive rats on high salt diet. Hypertension 2003;41:592-597.
- Kobori H, Nishiyama A, Harrison-Bernard LM, Navar LG. Urinary angiotensinogen as an indicator of intrarenal angiotensin status in hypertension. Hypertension 2003;41:42-49.
- 15. Yamamoto T, Nakagawa T, Suzuki H, et al. Urinary angiotensinogen as a marker of intrarenal angiotensin II activity associated with deterioration of renal function in patients with chronic kidney disease. J Am Soc Nephrol

2007;18:1558-1565.

- Urushihara M, Kondo S, Kagami S, Kobori H. Urinary angiotensinogen accurately reflects intrarenal Renin-Angiotensin system activity. Am J Nephrol 2010;31:318-325.
- Nishiyama A, Konishi Y, Ohashi N, et al. Urinary angiotensinogen reflects the activity of intrarenal renin-angiotensin system in patients with IgA nephropathy. Nephrol Dial Transplant 2011;26:170-177.
- Mills KT, Kobori H, Hamm LL, et al. Increased urinary excretion of angiotensinogen is associated with risk of chronic kidney disease. Nephrol Dial Transplant 2012;27:3176-3181.
- Wu H, Liang Y, Zheng Y, et al. Up-regulation of intrarenal renin-agiotensin system contributes to renal damage in high-salt induced hypertension rats. Kidney Blood Press Res 2014;39:526-535.
- 20. Oh KH, Park SK, Park HC, et al. KNOW-CKD (KoreaN cohort study for Outcome in patients With Chronic Kidney Disease): design and methods. BMC Nephrol 2014;15:80.
- 21. Levey AS, Coresh J, Greene T, et al. Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Ann Intern Med 2006;145:247-254.
- 22. Katsurada A, Hagiwara Y, Miyashita K, et al. Novel sandwich ELISA for human angiotensinogen. Am J Physiol Renal Physiol 2007;293:F956-F960.
- 23. Aburto NJ, Ziolkovska A, Hooper L, Elliott P, Cappuccio FP, Meerpohl JJ. Effect of lower sodium intake on health: systematic review and meta-analyses. BMJ 2013;346:fi326.
- 24. He FJ, Li J, Macgregor GA. Effect of longer term modest salt reduction on blood pressure: cochrane systematic review and meta-analysis of randomized trials. BMJ 2013;346:fi325.
- 25. Cook NR, Appel LJ, Whelton PK. Sodium intake and allcause mortality over 20 years in the trials of hypertension prevention. J Am Coll Cardiol 2016;68:1609-1617.
- 26. Oh J, Lee J, Koo HS, Kim S, Chin HJ. Estimated 24-hour urine sodium excretion is correlated with blood pressure in Korean population: 2009-2011 Korean National Health and Nutritional Examination Survey. J Korean Med Sci 2014;29 Suppl 2(Suppl 2):S109-S116.
- 27. Sanada H, Jones JE, Jose PA. Genetics of salt-sensitive hypertension. Curr Hypertens Rep 2011;13:55-66.
- 28. Intersalt Cooperative Research Group. Intersalt: an international study of electrolyte excretion and blood pressure. Results for 24 hour urinary sodium and potassium



excretion. BMJ 1988;297:319-328.

- 29. Cutler JA, Follmann D, Allender PS. Randomized trials of sodium reduction: an overview. Am J Clin Nutr 1997;65(2 Suppl):643S-651S.
- 30. He J, Ogden LG, Vupputuri S, Bazzano LA, Loria C, Whelton PK. Dietary sodium intake and subsequent risk of cardiovascular disease in overweight adults. JAMA 1999;282:2027-2034.
- 31. Sacks FM, Svetkey LP, Vollmer WM, et al. Effects on blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH) diet. DASH-Sodium Collaborative Research Group. N Engl J Med 2001;344:3-10.
- 32. Giner V, Poch E, Bragulat E, et al. Renin-angiotensin sys-

tem genetic polymorphisms and salt sensitivity in essential hypertension. Hypertension 2000;35(1 Pt 2):512-517.

- 33. Poch E, Gonzalez D, Giner V, Bragulat E, Coca A, de La Sierra A. Molecular basis of salt sensitivity in human hypertension. Evaluation of renin-angiotensin-aldosterone system gene polymorphisms. Hypertension 2001;38:1204-1209.
- 34. Hasimu B, Nakayama T, Mizutani Y, et al. Haplotype analysis of the human renin gene and essential hypertension. Hypertension 2003;41:308-312.
- 35. Gu JW, Bailey AP, Tan W, Shparago M, Young E. Longterm high salt diet causes hypertension and decreases renal expression of vascular endothelial growth factor in Sprague-Dawley rats. J Am Soc Hypertens 2008;2:275-285.



Predictor (response = systolic blood pressure)	Coefficient (95% CI)	Standardized coefficient (95% CI)	p value
Age	0.071 (0.015 to 0.126)	0.053 (0.011 to 0.095)	0.013
Sex			< 0.001
Male vs. Female	3.131 (1.727 to 4.535)	0.092 (0.051 to 0.134)	< 0.001
eGFR category	-0.061 (-0.083 to -0.038)	–0.111 (–0.153 to –0.07)	< 0.001
Body mass index	0.67 (0.469 to 0.872)	0.138 (0.096 to 0.179)	< 0.001
Hemoglobin	–0.554 (–0.896 to –0.212)	-0.068 (-0.11 to -0.026)	0.002
Waist-to-hip ratio	43.847 (33.225 to 54.469)	0.175 (0.133 to 0.218)	< 0.001
24-hour UNa	0.024 (0.013 to 0.034)	0.1 (0.055 to 0.144)	< 0.001
UACR	3.105 (1.822 to 4.389)	0.153 (0.09 to 0.216)	< 0.001
Log UAGT/Cr	2.141 (0.98 to 3.303)	0.088 (0.04 to 0.135)	< 0.001
ACEIs or ARBs	2.076 (0.122 to 4.03)	0.044 (0.003 to 0.086)	0.037
eGFR category, mL/min/1.73 m ² (%)			< 0.001
60–90 vs. > 90	1.394 (–1.137 to 3.925)	0.125 (-0.102 to 0.352)	0.28
45–59 vs. > 90	1.452 (–1.101 to 4.006)	0.13 (–0.099 to 0.359)	0.265
30–44 vs. > 90	2.033 (-0.429 to 4.495)	0.182 (-0.038 to 0.403)	0.106
15–29 vs. > 90	4.131 (1.699 to 6.564)	0.37 (0.152 to 0.588)	< 0.001
< 15 vs. > 90	8.997 (5.652 to 12.341)	0.806 (0.506 to 1.106)	< 0.001
eGFR category (two groups), mL/min/1.73 m ² (%)			0.009
≤ 90 VS. > 90	2.841 (0.719 to 4.963)	0.056 (0.014 to 0.097)	0.009
Etiology of CKD			< 0.001
Diabetic nephropathy	4.787 (1.748 to 7.825)	0.376 (0.137 to 0.615)	0.002
Hypertensive nephropathy	-2.015 (-5.136 to 1.107)	-0.158 (-0.404 to 0.087)	0.206
Glomerulonephritis	–5.861 (–8.782 to –2.94)	-0.461 (-0.69 to -0.231)	< 0.001
Polycystic kidney disease	–1.308 (–4.475 to 1.859)	–0.103 (–0.352 to 0.146)	0.418

Supplementary Table 1. Results of the univariable linear regression analysis using the systolic blood pressure as the response

CI, confidence interval; eGFR, estimated glomerular filtration rate; 24-hour UNa, 24-hour urinary sodium; UACR, urine albumin-to-creatinine ratio; Log, logarithm; UAGT, urine angiotensinogen; ACEI, angiotensin-converting-enzyme inhibitor; ARB, angiotensin receptor blocker; CKD chronic kidney disease.